Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
-
BUSINESS FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
-
BUSINESS FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
-
REGULATORY MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
-
BUSINESS Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
-
REGULATORY Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
-
REGULATORY MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
-
TRENDS Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
REGULATORY Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
-
REGULATORY Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
-
REGULATORY (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
-
REGULATORY 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
-
REGULATORY Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
-
BUSINESS Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
-
BUSINESS Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
-
BUSINESS Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
-
BUSINESS Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
-
BUSINESS Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
-
BUSINESS Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
-
REGULATORY LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…